Small Molecule · HS-10380
Obuprazine (HS-10380)
Obuprazine (HS-10380) is an oral, once-daily investigational antipsychotic discovered and developed by Hansoh Pharma (China). Hansoh describes it as a multi-target agent that is a partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors with potent 5-HT2A antagonism, intended to improve positive, negative and cognitive symptoms of schizophrenia. In a 363-patient Chinese Phase 2b trial in acute schizophrenia (NCT07550387), all three dose ranges (1.5-3 mg, 4.5-6 mg, 6-9 mg) beat placebo on the PANSS total score at Day 42, with aripiprazole as active control; Hansoh reported the safety profile as generally favorable and said the results support moving into Phase 3.
Also known as: HS-10380, HS 10380, HS10380, obuprazine, 2640663-79-0, N-(trans-3-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclobutyl)-1,3-oxazole-2-carboxamide
Key facts
- Modality
- Small molecule
- Chemical class
- arylpiperazine, cyclobutane, oxazole
- Chemistry
- Achiral
- Mechanism
- D2 Partial agonist
- Highest phase
- Phase 2
- Lead indication
- Schizophrenia
- Developer
- Jiangsu Hansoh Pharmaceutical Co., Ltd. (3692.HK)
- Trials
- 4 tracked · 2 sites
Mechanism of action#
Per Hansoh, obuprazine is a partial agonist at dopamine D2 and D3 receptors and at serotonin 5-HT1A receptors, with potent antagonism at 5-HT2A receptors, a multi-target profile intended to improve positive, negative and cognitive symptoms while reducing adverse effects. No binding affinities or functional potencies have been published.
Formulations#
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Obuprazine (HS-10380) oral tablet, once daily Phase 2b (NCT07550387): fixed-flexible once-daily oral 1.5-3 mg, 4.5-6 mg or 6-9 mg each morning for 42 days, then a 1-week taper. Phase 1b/2 (NCT05964790): tablet orally once daily for 28 days. Phase 3 long-term safety study (NCT07759869): 1.5-6 mg. | Oral | Once daily | — |
Development timeline#
- metPhase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.↗
- Trial registeredPhase 3 long-term safety study of HS-10380 in schizophrenia registered
- Trial (portion) completedPhase 2b of HS-10380 in acute schizophrenia completes
- IND/CTA clearanceChina CDE approves clinical trials of HS-10380 in manic episodes of bipolar I disorder↗
- Phase 2b in hospitalized adults with acute schizophrenia (NCT07550387, HS-10380-202) started (actual date per ClinicalTrials.gov); primary completion 2026-01-02, study completion 2026-01-19. Registered retrospectively (first posted 2026-04-24).
- Trial startedPhase 2b of HS-10380 in acute schizophrenia starts
- Phase 1b/2 in Chinese adults with schizophrenia (NCT05964790, HS-10380-201) registered with an ESTIMATED start of 2023-07-30; the record was never updated (status UNKNOWN), so the date is approximate.
- First-in-human SAD/MAD study in Chinese healthy adults (NCT05480592, HS-10380-101) started per ClinicalTrials.gov (registered under schizophrenia; record status since UNKNOWN).
Obuprazine (HS-10380) for Schizophrenia#
Phase 2ActiveSchizophrenia indication →
Obuprazine (HS-10380), an oral D2/D3 and 5-HT1A partial agonist with potent 5-HT2A antagonism from Hansoh Pharma, for schizophrenia in China. The Phase 2b trial (NCT07550387, HS-10380-202) randomized 363 Chinese adults hospitalized with acute schizophrenia to three once-daily dose ranges (1.5-3 mg, 4.5-6 mg, 6-9 mg), aripiprazole or placebo for 42 days. All three doses met the primary endpoint, with least-squares mean differences in PANSS total score change versus placebo of -16.7, -13.2 and -14.7 (aripiprazole -12.1), plus improvements in positive, negative and cognitive domains. Hansoh said safety was generally favorable with mostly mild-to-moderate adverse events, and that the results support moving into Phase 3. The data were presented at ECNP 2026 in Munich on 2026-10-10.
Readouts
- 2026-10-10ReportedFull resultsmetNCT07550387
Phase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026. ↗
Clinical trials#
NCT07759869HS-10380-303Phase 3Activen=500
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety of HS-10380 in Chinese Adult Patients With Schizophrenia
NCT07550387HS-10380-202Phase 2Completedn=363
A Randomized, Double-Blind, Active-Controlled and Placebo-Controlled Phase 2b Clinical Study to Evaluate the Efficacy and Safety of HS-10380 in Chinese Adult Patients With Acute Schizophrenia
China
NCT05964790HS-10380-201Phase 1/2Unknownn=112
A Phase Ib/II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia
NCT05480592HS-10380-101Phase 1Unknownn=76
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HS-10380 in Chinese Healthy Adult Subjects
China
Conference coverage#
HS-10380 appears in 1 CNS Pulse conference abstract:
Sources#
- ECNP 2026 | Hansoh Pharma announces Phase 2b data of obuprazine (HS-10380) in schizophrenia (2026-10-12) — Hansoh Pharmaceutical Group
- Hansoh Pharma's Class 1 innovative drug approved for clinical trials, intended to treat manic episodes of bipolar I disorder (2024-07-24) — Longbridge / Zhitong Finance
- HS-10380 in patients with schizophrenia: a phase 2b randomised placebo- and active-controlled trial (ECNP 2026, PS01-1227) — CNS Pulse (ECNP 2026 abstract)
- NCT05480592 (HS-10380-101) — Phase 1 SAD/MAD in Chinese healthy adults — ClinicalTrials.gov
- NCT05964790 (HS-10380-201) — Phase 1b/2 in Chinese adults with schizophrenia — ClinicalTrials.gov
- NCT07550387 (HS-10380-202) — Phase 2b in acute schizophrenia — ClinicalTrials.gov
- NCT07759869 (HS-10380-303) — Phase 3 long-term safety in schizophrenia — ClinicalTrials.gov